Uriel Sandkovsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Uriel Sandkovsky has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Susan Swindells
Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, USA
7 shared publicationsCourtney V. Fletcher
Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, USA 2 Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA
3 shared publicationsAndre C. Kalil
Division of Infectious Diseases, Transplant Infectious Diseases Program, University of Nebraska Medical Center, Omaha, NE, USA
2 shared publicationsDiana F. Florescu
Division of Infectious Diseases, Transplant Infectious Diseases Program, University of Nebraska Medical Center, Omaha, NE, USA
2 shared publicationsEdward P. Acosta
Division of Clinical Pharmacology, University of Alabama Birmingham, Birmingham, Alabama, USA
2 shared publicationsHarlan Sayles
Department of Biostatistics and Center for Collaboration on Research, Design and Analysis, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA
2 shared publications
Latest Publications
- 1 December 2018
- Published by Elsevier in Transplantation Proceedings
- Vol. 50 (10) , 3763-3768
Risk Factors for the Development of Cytomegalovirus Resistance in Solid Organ Transplantation: A Retrospective Case-Control Study
- 1 December 2018
- Published by Elsevier in Transplantation Proceedings
- Vol. 50 (10) , 3763-3768
Risk Factors for the Development of Cytomegalovirus Resistance in Solid Organ Transplantation: A Retrospective Case-Control Study
- 1 April 2017
- Published by Elsevier in American Journal of Infection Control
- Vol. 45 (4) , 372-376
Bloodborne pathogen exposures: Difference in reporting rates and individual predictors among health care personnel
- 1 April 2017
- Published by Elsevier in American Journal of Infection Control
- Vol. 45 (4) , 372-376
Bloodborne pathogen exposures: Difference in reporting rates and individual predictors among health care personnel
- Open Access
- 21 September 2016
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 72 (1) , 200-204
Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients
Pharmacokinetics (PK) and pharmacodynamics of efavirenz and its 8-hydroxy metabolite (8-OH-efavirenz) have not been robustly evaluated in older HIV-infected persons. We investigated relationships between neuropsychological (NP) performance and efavirenz and 8-OH-efavirenz PK in HIV-infected individuals >50 years of age. A cross-sectional study of HIV-infected adults on an efavirenz-containing regimen. The 12 and 18 h post-dose plasma efavirenz and 8-OH-efavirenz were quantified. CYP2B6 polymorphisms were investigated. Participants underwent neuropsychological tests; surveys were used for depression, sleep quality and anxiety. We investigated potential correlations of efavirenz and 8-OH-efavirenz plasma concentrations with NP performance, sleep, depression, anxiety and CYP2B6 polymorphisms. Thirty participants (24 men and 6 women) with mean age 57 years (range 50–68). Plasma efavirenz concentrations did not correlate with NP performance; however, higher plasma 8-OH-efavirenz correlated with better learning (P = 0.002), language (P = 0.002) and total NP z-scores (P = 0.003). No correlation was seen for efavirenz or 8-OH-efavirenz with sleep, anxiety or depression. Median 12 and 18 h efavirenz plasma concentrations were 1967 ng/mL (IQR 1476–2394) and 1676 ng/mL (IQR 1120–2062), respectively. Median 12 and 18 h 8-OH-efavirenz plasma concentrations were 378 ng/mL (IQR 223–589) and 384 ng/mL (IQR 216–621), respectively. CYP2B6 G516T was associated with significantly higher plasma efavirenz at 12 and 18 h (P = 0.02) but not worse NP function. Better neurocognitive functioning was associated with higher 8-OH-efavirenz but not efavirenz plasma concentrations. No correlation was observed with sleep or depression. These findings point to a need for greater understanding of the metabolic profile of efavirenz and 8-OH-efavirenz in plasma and the CNS and relationships with antiviral effect and neurotoxicity.
- 21 September 2016
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 72 (1) , 200-204
Open AccessImpact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients
Pharmacokinetics (PK) and pharmacodynamics of efavirenz and its 8-hydroxy metabolite (8-OH-efavirenz) have not been robustly evaluated in older HIV-infected persons. We investigated relationships between neuropsychological (NP) performance and efavirenz and 8-OH-efavirenz PK in HIV-infected individuals >50 years of age. A cross-sectional study of HIV-infected adults on an efavirenz-containing regimen. The 12 and 18 h post-dose plasma efavirenz and 8-OH-efavirenz were quantified. CYP2B6 polymorphisms were investigated. Participants underwent neuropsychological tests; surveys were used for depression, sleep quality and anxiety. We investigated potential correlations of efavirenz and 8-OH-efavirenz plasma concentrations with NP performance, sleep, depression, anxiety and CYP2B6 polymorphisms. Thirty participants (24 men and 6 women) with mean age 57 years (range 50–68). Plasma efavirenz concentrations did not correlate with NP performance; however, higher plasma 8-OH-efavirenz correlated with better learning (P = 0.002), language (P = 0.002) and total NP z-scores (P = 0.003). No correlation was seen for efavirenz or 8-OH-efavirenz with sleep, anxiety or depression. Median 12 and 18 h efavirenz plasma concentrations were 1967 ng/mL (IQR 1476–2394) and 1676 ng/mL (IQR 1120–2062), respectively. Median 12 and 18 h 8-OH-efavirenz plasma concentrations were 378 ng/mL (IQR 223–589) and 384 ng/mL (IQR 216–621), respectively. CYP2B6 G516T was associated with significantly higher plasma efavirenz at 12 and 18 h (P = 0.02) but not worse NP function. Better neurocognitive functioning was associated with higher 8-OH-efavirenz but not efavirenz plasma concentrations. No correlation was observed with sleep or depression. These findings point to a need for greater understanding of the metabolic profile of efavirenz and 8-OH-efavirenz in plasma and the CNS and relationships with antiviral effect and neurotoxicity.
- 22 June 2015
- Published by Wiley in Clinical Transplantation
- Vol. 29 (8) , 689-696
The use and value of procalcitonin in solid organ transplantation
Procalcitonin (PCT) has been increasingly used as a biomarker of bacterial infection and as a tool to guide antimicrobial therapy, especially in lower respiratory tract and bloodstream infections. Despite its increased use, data in patients with solid organ transplants are limited. Even without the presence of infection, PCT increases as a result of surgical procedures during transplantation, implantation of devices, and use of induction immunosuppressive therapy. The risk of infection is also higher in solid organ transplant recipients when compared to the general population. Monitoring PCT in the early post‐transplant period seems to be a promising method for early detection of infectious complications. It has been shown that elevatedPCTlevels after one wk of transplantation are correlated with infectious complications.PCTmay be a useful adjunctive biomarker that may improve early identification and guide appropriate treatment of infection or rejection, with the potential to further improve clinical outcomes. The use of serialPCTmeasurements may be more reliable than single values. It is important to recognize which factors may lead to PCT increases in the post‐transplantation period, which in turn will help understand the kinetics and utility of this biomarker in this important patient population.
- 22 June 2015
- Published by Wiley in Clinical Transplantation
- Vol. 29 (8) , 689-696
The use and value of procalcitonin in solid organ transplantation
Procalcitonin (PCT) has been increasingly used as a biomarker of bacterial infection and as a tool to guide antimicrobial therapy, especially in lower respiratory tract and bloodstream infections. Despite its increased use, data in patients with solid organ transplants are limited. Even without the presence of infection, PCT increases as a result of surgical procedures during transplantation, implantation of devices, and use of induction immunosuppressive therapy. The risk of infection is also higher in solid organ transplant recipients when compared to the general population. Monitoring PCT in the early post‐transplant period seems to be a promising method for early detection of infectious complications. It has been shown that elevatedPCTlevels after one wk of transplantation are correlated with infectious complications.PCTmay be a useful adjunctive biomarker that may improve early identification and guide appropriate treatment of infection or rejection, with the potential to further improve clinical outcomes. The use of serialPCTmeasurements may be more reliable than single values. It is important to recognize which factors may lead to PCT increases in the post‐transplantation period, which in turn will help understand the kinetics and utility of this biomarker in this important patient population.
- 2 March 2015
- Published by BMJ in BMJ Case Reports
- Vol. 2015
Acute suppurative parotitis caused byStreptococcus pneumoniaein an HIV-infected man
We report a case of a 32-year-old man who presented with progressive unilateral parotid gland enlargement and subsequently tested positive for HIV. A CT scan of the neck performed with contrast showed a phlegmon in the region of the right parotid tail measuring approximately 2.5×2.4 cm. Cultures of the aspirated fluid grewStreptococcus pneumoniaeand theS. pneumoniaeurinary antigen test was also positive. The patient underwent surgical debridement and received antimicrobial therapy with complete resolution of the parotitis. Parotitis caused byS. pneumoniaeis rare, and HIV infection should be suspected in any case of invasive pneumococcal disease.
- 2 March 2015
- Published by BMJ in BMJ Case Reports
- Vol. 2015
Acute suppurative parotitis caused byStreptococcus pneumoniaein an HIV-infected man
We report a case of a 32-year-old man who presented with progressive unilateral parotid gland enlargement and subsequently tested positive for HIV. A CT scan of the neck performed with contrast showed a phlegmon in the region of the right parotid tail measuring approximately 2.5×2.4 cm. Cultures of the aspirated fluid grewStreptococcus pneumoniaeand theS. pneumoniaeurinary antigen test was also positive. The patient underwent surgical debridement and received antimicrobial therapy with complete resolution of the parotitis. Parotitis caused byS. pneumoniaeis rare, and HIV infection should be suspected in any case of invasive pneumococcal disease.
- 1 July 2014
- Published by SAGE Publications in Antiviral Therapy
- Vol. 20 (5) , 555-559
Impact of an Electronic Medical Record on the Incidence of Antiretroviral Prescription Errors and HIV Pharmacist Reconciliation on Error Correction among Hospitalized HIV-Infected Patients
Background: Previous review of admissions from 2009–2011 in our institution found a 35.1% error rate in antiretroviral (ART) prescribing, with 55% of errors never corrected. Subsequently, our institution implemented a unified electronic medical record (EMR) and we developed a medication reconciliation process with an HIV pharmacist. We report the impact of the EMR on incidence of errors and of the pharmacist intervention on time to error correction. Methods: Prospective medical record review of HIV-infected patients hospitalized for >24 h between 9 March 2013 and 10 March 2014. An HIV pharmacist reconciled outpatient ART prescriptions with inpatient orders within 24 h of admission. Prescribing errors were classified and time to error correction recorded. Error rates and time to correction were compared to historical data using relative risks (RR) and logistic regression models. Results: 43 medication errors were identified in 31/186 admissions (16.7%). The incidence of errors decreased significantly after EMR (RR 0.47, 95% CI 0.34, 0.67). Logistic regression adjusting for gender and race/ethnicity found that errors were 61% less likely to occur using the EMR (95% CI 40%, 75%; P<0.001). All identified errors were corrected, 65% within 24 h and 81.4% within 48 h. Compared to historical data where only 31% of errors were corrected in <24 h and 55% were never corrected, errors were 9.4x more likely to be corrected within 24 h with HIV pharmacist intervention ( P<0.001). Conclusions: Use of an EMR decreased the error rate by more than 50% but despite this, ART errors remained common. HIV pharmacist intervention was key to timely error correction.
- 1 July 2014
- Published by SAGE Publications in Antiviral Therapy
- Vol. 20 (5) , 555-559
Impact of an Electronic Medical Record on the Incidence of Antiretroviral Prescription Errors and HIV Pharmacist Reconciliation on Error Correction among Hospitalized HIV-Infected Patients
Background: Previous review of admissions from 2009–2011 in our institution found a 35.1% error rate in antiretroviral (ART) prescribing, with 55% of errors never corrected. Subsequently, our institution implemented a unified electronic medical record (EMR) and we developed a medication reconciliation process with an HIV pharmacist. We report the impact of the EMR on incidence of errors and of the pharmacist intervention on time to error correction. Methods: Prospective medical record review of HIV-infected patients hospitalized for >24 h between 9 March 2013 and 10 March 2014. An HIV pharmacist reconciled outpatient ART prescriptions with inpatient orders within 24 h of admission. Prescribing errors were classified and time to error correction recorded. Error rates and time to correction were compared to historical data using relative risks (RR) and logistic regression models. Results: 43 medication errors were identified in 31/186 admissions (16.7%). The incidence of errors decreased significantly after EMR (RR 0.47, 95% CI 0.34, 0.67). Logistic regression adjusting for gender and race/ethnicity found that errors were 61% less likely to occur using the EMR (95% CI 40%, 75%; P<0.001). All identified errors were corrected, 65% within 24 h and 81.4% within 48 h. Compared to historical data where only 31% of errors were corrected in <24 h and 55% were never corrected, errors were 9.4x more likely to be corrected within 24 h with HIV pharmacist intervention ( P<0.001). Conclusions: Use of an EMR decreased the error rate by more than 50% but despite this, ART errors remained common. HIV pharmacist intervention was key to timely error correction.
- 1 November 2013
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 21 (6) , 383-385
Disseminated Histoplasmosis Presenting as Esophageal Ulceration in an HIV-Infected Man
A 30-year-old man with advanced human immunodeficiency virus–infection presented with worsening dysphagia and odynophagia of 4 months’ duration. He had been on a revised combination antiretroviral regimen for 3 months with a recent CD4 count of 57 cells/mm3 and human immunodeficiency virus viral load of less than 50 copies/mL. Esophagogastroduodenoscopy showed erosive esophagitis and esophageal ulcers. Histopathologic examination was negative for herpes viruses and cytomegalovirus but showed intracellular yeast consistent with histoplasmosis. Histoplasma antigenuria was more than 39 ng/mL, which confirmed the diagnosis of disseminated histoplasmosis. After 3 weeks of treatment with liposomal amphotericin B and significant improvement, antifungal therapy was changed to itraconazole suspension. Histoplasma capsulatum is well known to cause gastrointestinal involvement in patients with acquired immunodeficiency syndrome, but esophageal involvement is rare.
- 1 November 2013
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 21 (6) , 383-385
Disseminated Histoplasmosis Presenting as Esophageal Ulceration in an HIV-Infected Man
A 30-year-old man with advanced human immunodeficiency virus–infection presented with worsening dysphagia and odynophagia of 4 months’ duration. He had been on a revised combination antiretroviral regimen for 3 months with a recent CD4 count of 57 cells/mm3 and human immunodeficiency virus viral load of less than 50 copies/mL. Esophagogastroduodenoscopy showed erosive esophagitis and esophageal ulcers. Histopathologic examination was negative for herpes viruses and cytomegalovirus but showed intracellular yeast consistent with histoplasmosis. Histoplasma antigenuria was more than 39 ng/mL, which confirmed the diagnosis of disseminated histoplasmosis. After 3 weeks of treatment with liposomal amphotericin B and significant improvement, antifungal therapy was changed to itraconazole suspension. Histoplasma capsulatum is well known to cause gastrointestinal involvement in patients with acquired immunodeficiency syndrome, but esophageal involvement is rare.
- Open Access
- 16 August 2013
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 69 (1) , 262-267
Antiretroviral medication prescribing errors are common with hospitalization of HIV-infected patients
Errors in prescribing antiretroviral therapy (ART) often occur with the hospitalization of HIV-infected patients. The rapid identification and prevention of errors may reduce patient harm and healthcare-associated costs. A retrospective review of hospitalized HIV-infected patients was carried out between 1 January 2009 and 31 December 2011. Errors were documented as omission, underdose, overdose, duplicate therapy, incorrect scheduling and/or incorrect therapy. The time to error correction was recorded. Relative risks (RRs) were computed to evaluate patient characteristics and error rates. A total of 289 medication errors were identified in 146/416 admissions (35%). The most common was drug omission (69%). At an error rate of 31%, nucleoside reverse transcriptase inhibitors were associated with an increased risk of error when compared with protease inhibitors (RR 1.32; 95% CI 1.04–1.69) and co-formulated drugs (RR 1.59; 95% CI 1.19–2.09). Of the errors, 31% were corrected within the first 24 h, but over half (55%) were never remedied. Admissions with an omission error were 7.4 times more likely to have all errors corrected within 24 h than were admissions without an omission. Drug interactions with ART were detected on 51 occasions. For the study population (n = 177), an increased risk of admission error was observed for black (43%) compared with white (28%) individuals (RR 1.53; 95% CI 1.16–2.03) but no significant differences were observed between white patients and other minorities or between men and women. Errors in inpatient ART were common, and the majority were never detected. The most common errors involved omission of medication, and nucleoside reverse transcriptase inhibitors had the highest rate of prescribing error. Interventions to prevent and correct errors are urgently needed.
- 16 August 2013
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 69 (1) , 262-267
Open AccessAntiretroviral medication prescribing errors are common with hospitalization of HIV-infected patients
Errors in prescribing antiretroviral therapy (ART) often occur with the hospitalization of HIV-infected patients. The rapid identification and prevention of errors may reduce patient harm and healthcare-associated costs. A retrospective review of hospitalized HIV-infected patients was carried out between 1 January 2009 and 31 December 2011. Errors were documented as omission, underdose, overdose, duplicate therapy, incorrect scheduling and/or incorrect therapy. The time to error correction was recorded. Relative risks (RRs) were computed to evaluate patient characteristics and error rates. A total of 289 medication errors were identified in 146/416 admissions (35%). The most common was drug omission (69%). At an error rate of 31%, nucleoside reverse transcriptase inhibitors were associated with an increased risk of error when compared with protease inhibitors (RR 1.32; 95% CI 1.04–1.69) and co-formulated drugs (RR 1.59; 95% CI 1.19–2.09). Of the errors, 31% were corrected within the first 24 h, but over half (55%) were never remedied. Admissions with an omission error were 7.4 times more likely to have all errors corrected within 24 h than were admissions without an omission. Drug interactions with ART were detected on 51 occasions. For the study population (n = 177), an increased risk of admission error was observed for black (43%) compared with white (28%) individuals (RR 1.53; 95% CI 1.16–2.03) but no significant differences were observed between white patients and other minorities or between men and women. Errors in inpatient ART were common, and the majority were never detected. The most common errors involved omission of medication, and nucleoside reverse transcriptase inhibitors had the highest rate of prescribing error. Interventions to prevent and correct errors are urgently needed.
- 1 August 2013
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 14 (4) , 165-174
Pilot Study of Younger and Older HIV-Infected Adults Using Traditional and Novel Functional Assessments
Objectives: Emerging data suggest that HIV disease and its treatment affect the aging process. Accurate and reliable measures of functional status are needed to investigate this further. Design: A pilot study in groups of younger and older HIV-infected adults using objective measures of function. Methods: Evaluations included neuropsychological testing, grip strength, balance assessed by the Wii Balance Board, and actigraphy. Surveys were used for depression, fatigue, loneliness, self-reported activity level, and sexual function. Two-samplet test or Wilcoxon rank sum tests were used for continuous variables and exact chi-square tests were used for comparison between groups. Results: Twenty-one participants were 20 to 40 years old (younger; mean age, 31.5), and 20 were more than 50 years old (older; mean age, 56.5). There was no difference between groups for depression, fatigue, or loneliness. Overall, there was a trend to lower scores in the older age group for neuropsychologicalz score (P = .11) and for verbal learning (P = .09). Functioning in the memory domain was significantly lower in older subjects (P = .007). There was no difference in executive function, speed of processing, memory, motor skills, or total activity. Gender differences in sexual function were observed. Four older and 3 younger participants met the definition of frailty. Total activity by actigraphy did not correlate well with self-reported activity. Conclusions: Objective tests were well accepted and feasible to perform, although not all are suitable for widespread clinical or research use. Objective measurements of activity did not correlate well with patient self-report, which has implications for future studies in this area.
- 1 August 2013
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 14 (4) , 165-174
Pilot Study of Younger and Older HIV-Infected Adults Using Traditional and Novel Functional Assessments
Objectives: Emerging data suggest that HIV disease and its treatment affect the aging process. Accurate and reliable measures of functional status are needed to investigate this further. Design: A pilot study in groups of younger and older HIV-infected adults using objective measures of function. Methods: Evaluations included neuropsychological testing, grip strength, balance assessed by the Wii Balance Board, and actigraphy. Surveys were used for depression, fatigue, loneliness, self-reported activity level, and sexual function. Two-samplet test or Wilcoxon rank sum tests were used for continuous variables and exact chi-square tests were used for comparison between groups. Results: Twenty-one participants were 20 to 40 years old (younger; mean age, 31.5), and 20 were more than 50 years old (older; mean age, 56.5). There was no difference between groups for depression, fatigue, or loneliness. Overall, there was a trend to lower scores in the older age group for neuropsychologicalz score (P = .11) and for verbal learning (P = .09). Functioning in the memory domain was significantly lower in older subjects (P = .007). There was no difference in executive function, speed of processing, memory, motor skills, or total activity. Gender differences in sexual function were observed. Four older and 3 younger participants met the definition of frailty. Total activity by actigraphy did not correlate well with self-reported activity. Conclusions: Objective tests were well accepted and feasible to perform, although not all are suitable for widespread clinical or research use. Objective measurements of activity did not correlate well with patient self-report, which has implications for future studies in this area.
- 1 May 2013
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 17 (5) , e348-e351
Cytomegalovirus reactivation and colitis after left ventricular assist device placement
- 1 May 2013
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 17 (5) , e348-e351
Cytomegalovirus reactivation and colitis after left ventricular assist device placement